Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab

ConclusionsImprovements in HRQoL experienced by patients treated with eptinezumab can be substantially explained by its effect on migraine frequency and PI-MBS. Therefore, in addition to MMD reduction, healthcare providers should discuss PI-MBS improvements, since this may impact HRQoL. Health technology policymakers should consider implications of these findings in economic evaluation, as they point to alternative measurement of quality-adjusted life years to capture fully treatment benefits in cost-utility analyses.Trial registration ClinicalTrials.gov (Identifier:NCT04418765; EudraCT (Identifier: 2019 –004497-25; URL:https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004497-25).Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research